Ivermectin in Treatment of COVID-19

COVID Clinical Trial

Official title:

Use of Ivermectin as a Therapeutic Option for Patients With COVID-19

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04445311
• Other study ID #: ZU-IRB#6151/31-5-2020
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: May 31, 2020
• Est. completion date: August 15, 2020

Study information

• Verified date: June 2020
• Source: Zagazig University
• Contact: Waheed Shouman, MD
• Phone: +201114812048
• Email: shouman66[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

confirmed cases with COVID-19 will receive ivermectin as a therapeutic option as well as standard of care treatment and will be compared to those that will receive only standard of care ttt

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: August 15, 2020
• Est. primary completion date: July 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

COVID-19 patients during period of the study more than 18 years old

Exclusion Criteria:

refuse to participate pregnancy or lactation hypersensitivity to ivermectin receive any drug with interaction with ivermectin

Related Conditions & MeSH terms

• COVID

Intervention

Drug:
• Ivermectin
3 successive days ttt of ivermectin started within 48 hours of symptoms

Locations

Country	Name	City	State
Egypt	Waheed Shouman	Zagazig	Sharkia

Sponsors (1)

Lead Sponsor	Collaborator
Zagazig University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	time to be symptoms free	duration from day 1 symptoms till 3 days without symptoms	within 21 days after enrollment
Secondary	hospitalization	need hospital admission	within 21 days after enrollement
Secondary	Mechanical ventilation	need mechanical ventilation	within 21 days after enrollement
Secondary	length of stay	days spent in hospital	within one month days after enrollement
Secondary	mortality	survived or died	within one month days after enrollement